BKM120,
buparlisib,
NVP-BKM120,
944396-07-0,
Buparlisib,
NVP-BKM120,
BKM120,
5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine,
BKM-120,
NVP-BKM-120,
BKM 120,
1202777-78-3,
UNII-0ZM2Z182GD,
NVP-BKM 120,
5-[2,6-Di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine,
BKM120 (NVP-BKM120, Buparlisib),
5-[2,6-Di(Morpholin-4-Yl)pyrimidin-4-Yl]-4-(Trifluoromethyl)pyridin-2-Amine,
0ZM2Z182GD,
CHEMBL2017974,
CHEBI:71954,
AK103313,
5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-2-Pyridinamine,
C18H21F3N6O2,
2-Pyridinamine,5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-,
Buparlisib [USAN:INN],
BKM 120NX,
SD5,
Buparlisib; BKM120,
3sd5,
Buparlisib (USAN/INN),
QCR-4,
BKM120-NX,
MLS006010984,
SCHEMBL146956,
GTPL7878,
BKM120,NVP-BKM120,
AMMD00049,
CTK8C0567,
BMK-120,
DTXSID50241486,
EX-A189,
SYN1200,
CWHUFRVAEUJCEF-UHFFFAOYSA-N,
HMS3655D16,
AOB87379,
BKM120 (NVP-BKM120),
BKM120 - NVP-BKM120,
ABP000735,
ANW-64908,
BDBM50380363,
MFCD18251596,
s2247,
ZINC43154039,
AKOS016005372,
ACN-031536,
AM85983,
BCP9001011,
CS-0089,
DB11666,
RL05935,
SB16577,
BKM120 (NVP-BKM120 Buparlisib),
Buparlisib (BKM120, NVP-BKM120),
NCGC00262604-01,
NCGC00262604-08,
4CA-0929,
AN-26178,
AS-40568,
BC638775,
HY-70063,
SMR004702786,
AB0008183,
AJ-108243,
AX8234852,
DB-079882,
ST2411649,
TC-153653,
FT-0755923,
SW218149-2,
X7578,
KS-00000637,
A25436,
D10584,
W-5735,
J-516601,
BRD-K42191735-001-01-2,
4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine,
5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine,
5-(2,6-dimorpholin-4-ylpyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine,
2-Pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-,
5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine,
5-[2,6-bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine,
Buparlisib [INN],
D01QSO,
cc-258,
A3015,
A11016,
C571178,
Buparlisib, 98%, a selective PI3K inhibitor - 1G 1g,
1312445-63-8,